• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines N-acylpiperidines

Research Brief on 3-Chloro-1-(2-methylpiperidin-1-yl)propan-1-one (CAS: 349090-43-3): Recent Advances and Applications

3-Chloro-1-(2-methylpiperidin-1-yl)propan-1-one (CAS: 349090-43-3) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a key intermediate in the synthesis of pharmacologically active molecules, particularly those targeting central nervous system (CNS) disorders. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

A study published in the Journal of Medicinal Chemistry (2023) explored the use of 3-Chloro-1-(2-methylpiperidin-1-yl)propan-1-one as a precursor in the development of novel dopamine receptor modulators. The research team utilized a multi-step synthetic route, starting from 2-methylpiperidine, to obtain the target compound in high yield and purity. The compound's structural features, including the chloro and carbonyl functional groups, were found to be critical for its reactivity in subsequent coupling reactions.

In another recent investigation, researchers examined the compound's potential as a building block for the synthesis of sigma-1 receptor ligands. The study, published in Bioorganic & Medicinal Chemistry Letters (2024), demonstrated that derivatives of 3-Chloro-1-(2-methylpiperidin-1-yl)propan-1-one exhibited high affinity for sigma-1 receptors, which are implicated in various neurological and psychiatric disorders. These findings suggest that the compound could serve as a valuable scaffold for the development of new neuroprotective agents.

Pharmacokinetic studies have also been conducted to evaluate the compound's metabolic stability and bioavailability. A 2023 report in Drug Metabolism and Disposition indicated that 3-Chloro-1-(2-methylpiperidin-1-yl)propan-1-one demonstrates favorable metabolic properties, with moderate hepatic clearance and good permeability across biological membranes. These characteristics enhance its suitability as a lead compound for further optimization.

Despite these promising developments, challenges remain in the large-scale production and application of 3-Chloro-1-(2-methylpiperidin-1-yl)propan-1-one. Issues such as regioselectivity in subsequent derivatization reactions and potential toxicity profiles need to be addressed. Ongoing research is focused on refining synthetic methodologies and conducting comprehensive safety assessments to facilitate its broader use in drug development.

In conclusion, 3-Chloro-1-(2-methylpiperidin-1-yl)propan-1-one (CAS: 349090-43-3) represents a versatile and pharmacologically relevant compound with significant potential in medicinal chemistry. Recent advances in its synthesis and application underscore its value as a building block for CNS-targeted therapeutics. Future studies should aim to expand its utility and address existing limitations to fully realize its therapeutic potential.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)